Featured Research

from universities, journals, and other organizations

Deletion predicts survival in advanced non-small cell lung cancer

Date:
August 23, 2014
Source:
International Association for the Study of Lung Cancer
Summary:
Bcl-2-like protein 11 deletion in advanced non-small cell lung cancer is associated with shorter progression free survival in epidermal growth factor receptor tyrosine kinase inhibitor or chemotherapy treated Asian patients. Also, Bcl-2-like protein 11 deletion independently predicts overall survival of advanced non-small cell lung cancer patients.

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients. Also, BIM deletion independently predicts overall survival (OS) of advanced NSCLC patients.

Related Articles


The BIM protein can activate the programmed cell death also known as the apoptotic pathway in cells. BIM deletion has been detected in 12.8% of the Asian population but is very rarely observed in the Caucasian population. All NSCLC patients treated with any therapy, targeted or chemotherapeutic, ultimately fail their therapy but at varying times.

Researchers at the National Taiwan University Hospital examined the impact of BIM deletion on the survival outcomes of 204 advanced NSCLC patients treated with either EGFR TKIs or chemotherapy.

Results reported in the September issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), showed that BIM deletion was an independent predictive factor for shorter PFS in EGFR TKI treated patients (hazard ratio=2.15, p=0.002) with median PFS of 4.6 months in BIM deletion versus 8.6 months in wild type patients. Similar results were observed in chemotherapy treated patients with a hazard ratio of 2.4 (p=0.016) and median PFS of 3.5 and 5.6 months in deletion versus wild type, respectively. Overall survival was also independently predicted by BIM deletion (hazard ratio=1.65, p=0.039)

Dr. James Chih-Hsin Yang, senior author and member of IASLC, notes "our findings suggest the BIM deletion polymorphism should be considered as a clinical trial stratification factor when systemic treatment is considered in Asian NSCLC patients." Dr. Yang also says "since little is known about whether anti-apoptotic agents are able to overcome the resistance to EGFR TKIs resulting from BIM deletion, it may be warranted to explore anti-apoptotic agents, such as obatoclax, in future clinical trials."


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. The original article was written by Murry W. Wynes, PhD. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, Yih-Leong Chang, Jin-Yuan Shih, Yi-Nan Liu, Meng-Feng Tsai, Tzu-Hsiu Tsai, Chong-Jen Yu, James Chih-Hsin Yang, Pan-Chyr Yang. Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology, 2014; 9 (8): 1171 DOI: 10.1097/JTO.0000000000000232

Cite This Page:

International Association for the Study of Lung Cancer. "Deletion predicts survival in advanced non-small cell lung cancer." ScienceDaily. ScienceDaily, 23 August 2014. <www.sciencedaily.com/releases/2014/08/140823094342.htm>.
International Association for the Study of Lung Cancer. (2014, August 23). Deletion predicts survival in advanced non-small cell lung cancer. ScienceDaily. Retrieved April 19, 2015 from www.sciencedaily.com/releases/2014/08/140823094342.htm
International Association for the Study of Lung Cancer. "Deletion predicts survival in advanced non-small cell lung cancer." ScienceDaily. www.sciencedaily.com/releases/2014/08/140823094342.htm (accessed April 19, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, April 19, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Our Love Of Puppy Dog Eyes Explained By Science

Our Love Of Puppy Dog Eyes Explained By Science

Newsy (Apr. 17, 2015) Researchers found a spike in oxytocin occurs in both humans and dogs when they gaze into each other&apos;s eyes. Video provided by Newsy
Powered by NewsLook.com
Dr. Oz Under Fire For 'Quack Treatments' Yet Again

Dr. Oz Under Fire For 'Quack Treatments' Yet Again

Newsy (Apr. 17, 2015) Ten doctors signed a letter urging Columbia University to drop Dr. Oz as vice chair of its department of surgery, saying he plugs "quack" treatments. Video provided by Newsy
Powered by NewsLook.com
Scientists Find Link Between Gestational Diabetes And Autism

Scientists Find Link Between Gestational Diabetes And Autism

Newsy (Apr. 17, 2015) Researchers who analyzed data from over 300,000 kids and their mothers say they&apos;ve found a link between gestational diabetes and autism. Video provided by Newsy
Powered by NewsLook.com
Video Messages Help Reassure Dementia Patients

Video Messages Help Reassure Dementia Patients

AP (Apr. 17, 2015) Family members are prerecording messages as part of a unique pilot program at the Hebrew Home in New York. The videos are trying to help victims of Alzheimer&apos;s disease and other forms of dementia break through the morning fog of forgetfulness. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins